Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02386423 · ClinicalTrials.gov registry record · NA
RESTIFFIC™ Foot Wrap Reduces Moderate to Severe Restless Leg Syndrome
A NA study of Restless Leg Syndrome, sponsored by Lake Erie Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02386423: Completed NA study of Restless Leg Syndrome, sponsored by Lake Erie Research Institute.
NCT02386423 is a NA study of Restless Leg Syndrome that has completed, run by Lake Erie Research Institute. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02386423, a NA study of Restless Leg Syndrome, has completed, sponsored by Lake Erie Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety and efficacy of RESTIFFIC™, a foot wrap that produces adjustable targeted pressure on specific muscles in the feet, to reduce the symptoms of moderate to severe primary Restless Legs Syndrome.
Conditions Studied
Interventions
- DEVICE RESTIFFIC™ Brand Pressure Application System
Study Locations (1)
Pennsylvania
- Baycity Associated in Podiatry Inc - Erie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-04 |
| Est. Completion | 2011-11 |
| Phase | NA |
What the finished NCT02386423 record still lists
NCT02386423 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Restless Leg Syndrome appearing as the primary indexed condition, and to 1 intervention - of which RESTIFFIC™ Brand Pressure Application System is the first listed.
NCT02386423 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02386423 about?
NCT02386423 is a clinical study titled "RESTIFFIC™ Foot Wrap Reduces Moderate to Severe Restless Leg Syndrome". The purpose of this study is to determine the safety and efficacy of RESTIFFIC™, a foot wrap that produces adjustable targeted pressure on specific muscles in the feet, to reduce the symptoms of moderate to severe primary Restless Legs Syndrome.
What is the current status of trial NCT02386423?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2009-04. Estimated completion is 2011-11.
What conditions does trial NCT02386423 study?
This clinical trial studies the following conditions: Restless Leg Syndrome.
What interventions are being tested in trial NCT02386423?
The interventions under investigation include: RESTIFFIC™ Brand Pressure Application System (DEVICE).
Who is sponsoring clinical trial NCT02386423?
This trial is sponsored by Lake Erie Research Institute, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02386423 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Restless Leg Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02386423's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia